Kringle Pharma
Kringle Pharma is a late clinical-stage biopharmaceutical company focused on research and development of regenerative medicines.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| JPY | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (38 %) | 35 % | (82 %) | 16 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (37 %) | (124 %) | (109 %) | (1283 %) | (1022 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (25 %) | (104 %) | (85 %) | (1233 %) | (945 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Kringle Pharma is a late clinical stage biopharmaceutical company dedicated to the research, development, and commercialization of innovative medicines for patients suffering from incurable diseases. The company primarily focuses on conditions such as Acute Spinal Cord Injury and Amyotrophic Lateral Sclerosis (ALS). Operating in the global healthcare market, Kringle Pharma serves patients, healthcare providers, and medical institutions. The business model revolves around developing proprietary drug candidates through rigorous clinical trials and subsequently licensing these drugs to pharmaceutical companies for commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from drug sales.
Keywords: biopharmaceutical, clinical stage, spinal cord injury, ALS, innovative medicines, drug development, healthcare, licensing, commercialization, incurable diseases.